Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity
against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is …

In recent years, following the groundbreaking achievements of chimeric antigen receptor
(CAR) T cell therapy in hematological cancers, and advancements in cell engineering …

Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in
haematological malignancies. However, although viral vector-based methods are effective …

The successful application of CAR-T cells in the treatment of hematologic malignancies has
fundamentally changed cancer therapy. With increasing numbers of registered CAR-T cell …

Immune cell therapies with chimeric antigen receptor (CAR)-T and natural killer (NK) cells
have demonstrated groundbreaking therapeutic effects in hematological malignancies in the …